OMCL - Omnicell, Inc.
64.73 0.00 (0.00%)
After hours: 4:59PM EDT
| Previous Close | 63.39 |
| Open | 63.27 |
| Bid | 31.00 x 900 |
| Ask | 64.82 x 900 |
| Day's Range | 62.62 - 65.36 |
| 52 Week Range | 39.75 - 73.00 |
| Volume | 320,288 |
| Avg. Volume | 379,557 |
| Market Cap | 2.542B |
| Beta (3Y Monthly) | 0.74 |
| PE Ratio (TTM) | 67.99 |
| EPS (TTM) | 0.95 |
| Earnings Date | Oct 24, 2018 - Oct 29, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 65.25 |
- PR Newswire•6 days ago
Augusta University Health Selects Omnicell's Industry-Leading Medication Management Portfolio to Support Newly Redesigned Pharmacy
Solutions Leverage Automation to Help Optimize Hospital Workflows, Improve Financial Performance and Enhance Patient Safety MOUNTAIN VIEW, Calif. , Oct. 10, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: ...
- PR Newswire•28 days ago
Middlesex Hospital Bolsters Pharmacy Safety and Compliance by Extending Wolters Kluwer's Simplifi 797 with Omnicell's IVX Workflow
MOUNTAIN VIEW, Calif., Sept. 18, 2018 /PRNewswire/ -- Wolters Kluwer, Health and Omnicell, Inc. (OMCL) today announced that Connecticut-based Middlesex Hospital has extended its use of Simplifi 797® and has chosen Omnicell's IVX Workflow to automate the hospital's sterile compounding operations. The companies provide a turnkey solution that combines the expertise and best-practice approach of quality management solution Simplifi 797 with the advanced IVX Workflow technology from Omnicell. Scrutiny of compounding policies followed a high-profile meningitis outbreak in 2012 that brought to light weaknesses in the state-level oversight of these potentially risky drugs and the contamination-prone environments where they are formulated.
- Zacks•29 days ago
Omnicell Continues to Pursue Buyouts, Costs on the Rise
Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.
- PR Newswire•last month
Rob Seim to retire and join Omnicell Board of Directors
MOUNTAIN VIEW, Calif., Sept. 14, 2018 /PRNewswire/ -- Omnicell, Inc. (OMCL), the leading provider of medication and supply management technology across the continuum of care, today announced that Rob Seim, President of Global Automation and Medication Adherence, has indicated his intent to retire as of March 15, 2019. The company also announced the appointment of Mr. Seim to the Board of Directors following his retirement. Mr. Seim served Omnicell as its Chief Financial Officer for nearly 10 years and was also Executive Vice President of Finance, Administration, and Manufacturing during that time. For the past three years, Mr. Seim has served as President of Global Automation and Medication Adherence which includes responsibility for all of the non-US business of Omnicell, several product lines, and worldwide manufacturing. During his 13 years at Omnicell, revenue grew over 550% and market valuation grew over 8 fold.
- Simply Wall St.•last month
Has Omnicell Inc (NASDAQ:OMCL) Got Enough Cash?
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Omnicell Inc (NASDAQ:OMCL) with a market-capitalization of US$2.74b, rarely draw their attention. However, generally ignored mid-caps haveRead More...
- GlobeNewswire•last month
Recent Analysis Shows PennyMac Mortgage Investment Trust, Heritage Commerce, L Brands, Live Oak Bancshares, Northfield, and Omnicell Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Sept. 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•2 months ago
Omnicell Patient Engagement Unit to Aid Medication Adherence
Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.
- PR Newswire•2 months ago
Innovations to Omnicell Patient Engagement Platform Support Value-Based, Patient-Centered Care
Unified Platform for Clinical and Workflow Interventions Designed to Help Retail Pharmacies Improve Outcomes and Grow Business MOUNTAIN VIEW, Calif. , Aug. 23, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ:OMCL), ...
- Zacks•2 months ago
Options Traders Expect Huge Moves in Omnicell (OMCL) Stock
Omnicell (OMCL) needs investors to pay close attention to the stock based on moves in the options market lately.
- PR Newswire•2 months ago
Omnicell Exhibits Industry-Leading Platform with Suite of Automated Supply and Medication Management Solutions at AHRMM18
Company Hosts Reception at AHRMM Booth Exploring How Technology Helps to Increase Safety and Efficiency, While Lowering Costs MOUNTAIN VIEW, Calif. , Aug. 9, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: ...
- PR Newswire•2 months ago
Beaumont Health Selects Omnicell's Medication Management Platform and Services to Support Improved Financial and Clinical Performance
New Technology and Interoperability with Hospital's EHR Enhances Medication Inventory Visibility, Patient Safety MOUNTAIN VIEW, Calif. , Aug. 2, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL) today ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of OMCL earnings conference call or presentation 26-Jul-18 8:30pm GMT
Q2 2018 Omnicell Inc Earnings Call
- Motley Fool•3 months ago
Why Omnicell Is Soaring Today
Traders cheer after the company reports upbeat quarterly results and shares bullish guidance. Here's what investors need to know.
- Zacks•3 months ago
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q2
Omnicell's (OMCL) second-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.
- Associated Press•3 months ago
Omnicell: 2Q Earnings Snapshot
On a per-share basis, the Mountain View, California-based company said it had profit of 16 cents. Earnings, adjusted for one-time gains and costs, were 46 cents per share. The results beat Wall Street ...
- PR Newswire•3 months ago
Omnicell Announces Second Quarter 2018 Results
GAAP revenues of $189 million , up 4.2% year-over-year GAAP net income per diluted share of $0.16 , up $0.11 year-over-year Non-GAAP revenues of $189 million , up 4.0% year-over-year Non-GAAP net income ...
- PR Newswire•3 months ago
Advanced Pharmaceutical Consultants, Inc. Supports Behavioral Health Facilities with Omnicell's Secure Medication Management Technology
Automated Solutions Help Improve Medication Safety for Mental Health Patients Across the U.S. and its Territories MOUNTAIN VIEW, Calif. , July 25, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL) is ...
- Zacks•3 months ago
Medical Info Systems Stock Outlook: Short-Term Pain to Stay
Medical Info Systems Stock Outlook: Short-Term Pain to Stay
- PR Newswire•3 months ago
Omnicell to Release Second Quarter 2018 Earnings Results on July 26, 2018
MOUNTAIN VIEW, Calif. , July 19, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and adherence tools for healthcare systems and pharmacies, ...
- PR Newswire•3 months ago
NYU Langone Health Expands Strategic Partnership with Omnicell for Automated Medication Management Solutions
MOUNTAIN VIEW, Calif., July 19, 2018 /PRNewswire/ -- Omnicell, Inc. (OMCL) today announced that NYU Langone Health in New York has chosen the Company's automated medication management platform to help improve patient outcomes at its new inpatient hospital, the Helen L. and Martin S. Kimmel Pavilion. The addition of Omnicell® XT Automated Medication Dispensing Cabinets, Omnicell XT Anesthesia Workstation™, and Omnicell XT Controlled Substance Manager in the state-of-the-art facility builds on the health system's long-time relationship with Omnicell.
- Simply Wall St.•4 months ago
Is Omnicell Inc (NASDAQ:OMCL) A Sell At Its Current PE Ratio?
This article is intended for those of you who are at the beginning of your investing journey and want to better understand how you can grow your money by investingRead More...
- PR Newswire•4 months ago
STOMPP Study Demonstrates Multimed Packaging Improves Medication Adherence
MOUNTAIN VIEW, Calif., June 12, 2018 /PRNewswire/ -- Omnicell, Inc. (OMCL) announced the results of the STOMPP (Study to Measure the Impact of Pharmacists and Pharmacy Services on Medication Non-Adherence) clinical study. This randomized controlled trial compares the use of adherence medication packaging and medication therapy management (MTM) services to the use of traditional pill bottles. The results indicate a clear improvement in clinical outcomes and adherence rates when using multimed blister card packaging and MTM services.
- PR Newswire•5 months ago
Omnicell to Showcase Industry-Leading Medication Management Automation Platform at Annual ASHP Summer Meeting
Solutions to Help Improve Visibility, Streamline Workflows, and Support Patient Safety on Display in Booth #701 MOUNTAIN VIEW, Calif. , May 31, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading ...
- Zacks•5 months ago
Why Is Omnicell (OMCL) Up 2.6% Since Its Last Earnings Report?
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire•5 months ago
VitalConnect Announces Joe Lynch as Chief Marketing Officer
Experienced medtech marketing leader to drive continuous patient monitoring market strategy SAN JOSE, Calif. , May 24, 2018 /PRNewswire/ -- VitalConnect ® , Inc., a leader in wearable biosensor technology ...
